Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $295.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price upped by Stifel Nicolaus from $215.00 to $295.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on ALNY. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an equal weight rating in a research report on Tuesday, June 25th. Evercore ISI lifted their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an outperform rating in a research report on Tuesday, June 25th. TD Cowen raised their price target on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a buy rating in a report on Tuesday, June 25th. Finally, BMO Capital Markets reaffirmed an outperform rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $247.09.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $243.00 on Thursday. The company’s fifty day moving average price is $159.86 and its two-hundred day moving average price is $164.56. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $252.87. The company has a market capitalization of $30.74 billion, a price-to-earnings ratio of -90.67 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.40) EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -3.92 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CFO Jeffrey V. Poulton sold 1,605 shares of the firm’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $231.00, for a total value of $370,755.00. Following the transaction, the chief financial officer now directly owns 28,892 shares in the company, valued at approximately $6,674,052. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total value of $370,755.00. Following the completion of the sale, the chief financial officer now owns 28,892 shares of the company’s stock, valued at $6,674,052. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 2,103 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the completion of the sale, the chief marketing officer now owns 15,609 shares in the company, valued at $3,605,522.91. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,357 shares of company stock worth $13,436,711. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock valued at $562,000 after purchasing an additional 51 shares in the last quarter. EP Wealth Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 6.4% in the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 71 shares in the last quarter. Commerce Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 1.7% in the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock valued at $896,000 after buying an additional 77 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in shares of Alnylam Pharmaceuticals by 7.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 89 shares in the last quarter. Finally, Metis Global Partners LLC raised its holdings in shares of Alnylam Pharmaceuticals by 2.2% during the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after acquiring an additional 94 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.